Search Results - "Gaska, T."

Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial by Simon, F., Ligtvoet, R., Nösslinger, T., Bohn, J., Tresckow, J., Liersch, R., Gaska, T., Jentsch‐Ullrich, K., Koenigsmann, M., Wolff, T., Schwaner, I., Wolf, D., Schneider, C., Tausch, E., Stilgenbauer, S., Kreuzer, K., Robrecht, S., Fink, A., Fürstenau, M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B.

Get full text

A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX COMPARED TO OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA by Kutsch, N., Fink, A. M., Robrecht, S., Tausch, E., Schneider, C., Dierks, C., Wendtner, C., Meyer, R., Gaska, T., Chakupurakal, G., Jentsch‐Ullrich, K., Steiniger, H., Schwaner, I., Neumann, C., Fischer, K., Kreuzer, K., Ritgen, M., Stilgenbauer, S., Hallek, M., Eichhorst, B.

Get full text

Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany by Brueckl, W.M., Laack, E., Reck, M., Griesinger, F., Schäfer, H., Kortsik, C., Gaska, T., Rawluk, J., Krüger, S., Kokowski, K., Budweiser, S., Schueler, A., Kiessling, S.

Get full text

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL by Langerbeins, P., Robrecht, S., Nieper, P., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Fink, A., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Schneider, C., Müller, L., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Zahn, M., Dörfel, S., Eckart, M. J., Staib, P., Behlendorf, T., Hensel, M., Hebarth, H., Klaproth, H., Block, A., Liersch, R., Hauch, U., Heinrich, B., Wendtner, C., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.

Get full text

3032 A non-comparative, single-arm observational study conducted as a non-interventional study (NIS) to monitor the routine clinical practice of bevacizumab in combination with platinum-based chemotherapy in patients with unresectable advanced, metastatic or recurrent adenocarcinoma of the lung in Germany by Wirtz, H, Mezger, J, Gaska, T, Lerchenmueller, C, Reck, M, Reichert, D

Get full text

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL by Langerbeins, P., Bahlo, J., Rhein, C., Gerwin, H., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Tresckow, J., Fink, A.M., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Müller, L., Eckart, M., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Wendtner, C., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.

Get full text

1449PEfficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany by Brueckl, W M, Laack, E, Reck, M, Griesinger, F, Schäfer, H, Kortsik, C, Gaska, T, Rawluk, J, Krüger, S, Kokowski, K, Budweiser, S, Schueler, A, Kiessling, S

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Simon, F, Ligtvoet, R, Nösslinger, T, Bohn, J, von Tresckow, J, Liersch, R, Gaska, T, Jentsch-Ullrich, K, Koenigsmann, M, Wolff, T, Schwaner, I, Wolf, D, Schneider, C, Tausch, E, Stilgenbauer, S, Kreuzer, K, Robrecht, S, Fink, A, Fürstenau, M, Fischer, K, Goede, V, Hallek, M, Eichhorst, B

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Langerbeins, P, Robrecht, S, Nieper, P, Cramer, P, Fürstenau, M, Al-Sawaf, O, Fink, A, Kreuzer, K, Vehling-Kaiser, U, Tausch, E, Schneider, C, Müller, L, Schlag, R, Freier, W, Gaska, T, Balser, C, Reiser, M, Stauch, M, Zahn, M, Dörfel, S, Eckart, M J, Staib, P, Behlendorf, T, Hensel, M, Hebarth, H, Klaproth, H, Block, A, Liersch, R, Hauch, U, Heinrich, B, Wendtner, C, Fischer, K, Stilgenbauer, S, Eichhorst, B, Hallek, M

Get full text

Bevacizumab in routine clinical practice for first-line therapy with platinum-based chemotherapy of patients with advanced adenocarcinoma of the lung in Germany by Wirtz, H.R., Lang, S., Mezger, J., Hammerschmidt, S., Gaska, T., Lerchenmueller, C., Reck, M., Haas, S., Reichert, D., Hoeffken, G.

Get full text

Influence of donor lymphocytes on the incidence of primary graft failure after allogeneic bone marrow transplantation in a murine model by Uharek, L, Glass, B, Gaska, T, Gassmann, W, Loeffler, H, Mueller-Ruchholtz, W

“…We used a murine model to determine the impact of donor lymphocyte subsets on the incidence of primary marrow graft failure after transplantation of…”
Get more information

Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts by Zeis, M, Uharek, L, Glass, B, Gaska, T, Gassmann, W, Mueller-Ruchholtz, W

“…To investigate GVL effects, Balb/c mice (H-2d) received 5 x 10(5) A20 (B cell leukemia) or 1 x 10(6) WEHI-3 (myelomonocytic leukemia) cells. These cell lines…”
Get more information

Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model by Uharek, L, Glass, B, Gaska, T, Zeiss, M, Gassmann, W, Löffler, H, Müller-Ruchholtz, W

“…The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3…”
Get more information

The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment by Glass, B, Uharek, L, Gaska, T, Gassmann, W, Löffler, H, Müller-Ruchholtz, W

“…Graft rejection has hampered the use of T cell depletion (TCD) in allogeneic bone marrow transplantation. A model of host-versus-graft (HVGR) and…”
Get more information

The implementation of low latency communication primitives in the SNOW prototype by Ghose, K., Melnick, S., Gaska, T., Goldberg, S., Jayendran, A.K., Stein, B.T.

“…This paper describes the implementation of a low latency protected message passing facility and a low latency barrier synchronization mechanism for an…”
Get full text

Optimizing an incremental Modular Open System Approach (MOSA) in avionics systems for balanced architecture decisions by Gaska, T.

“…There is a need for incrementally optimizing the Modular Open Systems Approach (MOSA) being applied in open system based avionics platforms that include legacy…”
Get full text

Optimizing an incremental modular open system approach (MOSA) in avionics systems for balanced architecture decisions by Gaska, T.

“…The DoD preferred approach for implementation of open systems - Modular Open Systems Approach (MOSA) - Both a business and technical strategy for developing a…”
Get full text

Development of the LAMPS block II Advanced AYK-14 integrated mission processor by Gaska, T., Hrustich, J., Jackson, F., Layton, D., Reitz, D.

“…This paper provides an overview of the benchmark objectives, architecture tradeoffs and architecture validation of the Advanced AYK-14 (AAYK-14) as applied to…”
Get full text

Addressing challenges for GIG interoperability of manned and unmanned platforms by Gaska, T.

“…Affordably enabling the benefits of the Global Information Grid (GIG) for enhanced mission capabilities and effectiveness requires key decision coordination in…”
Get full text

Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice by Zeis, M, Uharek, L, Glass, B, Gaska, T, Steinmann, J, Gassmann, W, Löffler, H, Müller-Ruchholtz, W

Get more information